Conversely, tumor PD-L1 expression ≥90% was associated with longer OS in multivariable analyses of a large cohort of patients with metastatic NSCLC and PD-L1 expression ≥50% treated with first-line pembrolizumab monotherapy (23). This evidence concerns the gene CD274 and neoplasm.